Compare LGND & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LGND | ICUI |
|---|---|---|
| Founded | 1987 | 1984 |
| Country | United States | United States |
| Employees | 68 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.1B |
| IPO Year | N/A | 1995 |
| Metric | LGND | ICUI |
|---|---|---|
| Price | $224.32 | $115.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | ★ $256.29 | $169.00 |
| AVG Volume (30 Days) | 179.4K | ★ 222.8K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.62 |
| EPS | N/A | ★ 0.03 |
| Revenue | N/A | ★ $2,231,262,000.00 |
| Revenue This Year | $1.25 | N/A |
| Revenue Next Year | $19.41 | $4.46 |
| P/E Ratio | ★ $76.27 | $3,830.00 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $98.90 | $107.02 |
| 52 Week High | $247.38 | $160.29 |
| Indicator | LGND | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 53.61 | 33.34 |
| Support Level | $180.85 | $114.51 |
| Resistance Level | $227.92 | $133.16 |
| Average True Range (ATR) | 10.02 | 4.29 |
| MACD | -0.27 | -0.74 |
| Stochastic Oscillator | 51.79 | 16.56 |
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.